Apnimed Restates First Post-IPO Earnings on $85 Million Gain Misclassification
Company Background
Apnimed is a Cambridge, Massachusetts-based late-stage clinical pharmaceutical company focused on oral therapies for sleep-related breathing diseases. Its lead candidate, AD109, known by its proposed proprietary name Oxnimbi, is under FDA review; the agency assigned a PDUFA target action date of February 28, 2027. If approved, Oxnimbi would be the first oral pharmacological treatment targeting the neuromuscular root cause of obstructive sleep apnea.
Apnimed entered public markets on July 31, 2026, when its shares began trading on the Nasdaq Global Select Market. The IPO raised $220.8 million in gross proceeds and was accompanied by a senior secured credit facility of up to $150 million from funds managed by HealthCare Royalty Partners. The company used those proceeds partly to fund commercial readiness activities ahead of a potential Oxnimbi launch.
Apnimed disclosed a material weakness in internal controls in its original Q2 2026 Form 10-Q, citing an ineffective control environment that included insufficient accounting personnel to maintain proper controls over the classification, valuation, and disclosure of non-routine or complex transactions. That disclosure, made September 8, 2026, now frames the restatement that followed.
What Was Disclosed
Apnimed's Audit Committee, acting on management's recommendation, concluded on November 13, 2026 that the company's financial statements for the three and six months ended June 30, 2026 should no longer be relied upon. The error involves the $85.4 million gain Apnimed recognized when it sold its 50% interest in Shionogi-Apnimed Sleep Science, LLC to Shionogi & Co., Ltd. on April 6, 2026 pursuant to a Membership Interest and Asset Purchase Agreement dated March 23, 2026. That gain was recorded within other income from continuing operations, when accounting standard ASC 205-20 required it to be reported within discontinued operations.